Lilly's retatrutide results

Retatrutide is Lilly’s next obesity-and-diabetes drug candidate, and its first Phase 3 diabetes trial showed lower blood sugar and double-digit weight loss after 40 weeks. (lilly.com) Type 2 diabetes means the body struggles to keep blood sugar in range over time, and hemoglobin A1C is the lab test that tracks that average over about three months. In Lilly’s TRANSCEND-T2D-1 trial, retatrutide cut A1C by 1.7 to 2.0 percentage points across doses, compared with 0.8 points for placebo. (pharmacytimes.com) Weight loss was large, too: people on the 12-milligram dose lost an average 36.6 pounds, or 16.8% of body weight, by week 40. Lilly said participants were still losing weight at that point, with no plateau observed in the trial window. (lilly.com) Retatrutide targets three hormone pathways — glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon — while Lilly’s marketed drug tirzepatide targets two. Lilly described retatrutide as an investigational “triple agonist” being tested as an add-on to diet and exercise in adults whose diabetes was not controlled by diet and exercise alone. (lilly.com) TRANSCEND-T2D-1 enrolled 537 adults with a mean baseline A1C of 7.9%, a mean body mass index of 35.8, and a mean type 2 diabetes duration of 2.5 years. Participants were randomized to retatrutide 4, 9, or 12 milligrams or placebo, starting at 2 milligrams and stepping up every four weeks. (pharmacytimes.com) Lilly also said retatrutide improved several cardiometabolic measures, including non-high-density lipoprotein cholesterol, triglycerides, and systolic blood pressure. The company said the most common side effects were gastrointestinal and were “generally consistent” with incretin-based therapies, with nausea, vomiting, diarrhea, and constipation reported more often than with placebo. (lilly.com) The result matters inside Lilly’s broader race with Novo Nordisk and within Lilly’s own lineup, where Zepbound and Mounjaro already sell in obesity and diabetes. Retatrutide is still investigational, and Lilly said detailed Phase 3 results will be presented at a scientific meeting and published in a peer-reviewed journal. (lilly.com) Even as Lilly pushes newer drugs forward, Chief Executive David Ricks said demand will not automatically translate into universal use. Ricks said weight-loss drugs may reach only about half of eligible patients at peak because of healthcare-system complexity and financial limits. (thehindubusinessline.com) So the retatrutide story has two tracks at once: stronger late-stage data in diabetes, and a market where price, coverage, and access still cap how many people get treated. Lilly’s next step is to turn topline numbers into full data doctors, insurers, and regulators can scrutinize. (lilly.com)